Ceribell, Inc. CBLL

New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Cer

Strong growth driven by new FDA clearances, Delirium NTAP approval, and expanding account base despite widening net losses.

Moby summary of CeriBell, Inc.'s Q2 2026 earnings call

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 & Recent Highlights Reported total revenue of $28.1 million in the second quarter of 2026, a 33% increase compared to the same period in 2025Ended the quarter with 712 total

CeriBell Inc. (NASDAQ:CBLL) shares climbed about 3% after the company announced that the U.

Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring PlatformSUNNYVALE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for

Medtech Market-Builder Thomas West and Health System Operator Sharon O’Keefe Join Ceribell as Point-of-Care Brain Monitoring Advances Toward Standard of CareSUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O’Keefe to its Board of Directors. The new direct

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Easter

SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Monday, August 10, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 10,